LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 216 patients (estimated)
- Sponsors
- Incyte Corporation
- Tags
- Bromodomain and Extra-Terminal Protein (BET) Inhibitor, JAK1 Inhibitor, JAK2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1686
- NCT Identifier
- NCT04279847
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.